Harry J.M. Groen
YOU?
Author Swipe
View article: The influence of <i>ROS1</i> fusion partners and resistance mechanisms in <i>ROS1</i> ‐ <scp>TKI</scp> ‐treated non‐small cell lung cancer patients
The influence of <i>ROS1</i> fusion partners and resistance mechanisms in <i>ROS1</i> ‐ <span>TKI</span> ‐treated non‐small cell lung cancer patients Open
Clinical outcomes in ROS1 ‐fusion positive ( ROS1 +) non‐small cell lung cancer (NSCLC) by fusion partner and resistance mechanisms are limited. This cohort study included 56 ROS1+ patients (FISH or NGS confirmed); fusion partners were ide…
View article: DuTOC: The prospective Dutch Thoracic Oncology Cohort: A nationwide infrastructure to collect clinical data, PROMS and bio-material to support thoracic oncology studies
DuTOC: The prospective Dutch Thoracic Oncology Cohort: A nationwide infrastructure to collect clinical data, PROMS and bio-material to support thoracic oncology studies Open
The Dutch Thoracic Oncology Cohort (DuTOC) is a nationwide cohort for patients with thoracic malignancies collecting patient characteristics, quality of life and biomaterials after informed consent of the patient. With this data and materi…
View article: Cell-Free DNA Based Next-Generation Sequencing Does Not Differentiate Between Oligoprogression and Systemic Progression in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors—An Explorative Study
Cell-Free DNA Based Next-Generation Sequencing Does Not Differentiate Between Oligoprogression and Systemic Progression in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors—An Explorative Study Open
Immune checkpoint inhibitors (ICIs) are a key treatment for advanced non-small cell lung cancer (NSCLC), but most patients will ultimately experience disease progression due to acquired resistance to ICI. Clinically, it is relevant to diff…
View article: Cost-effectiveness and budget impact of lung cancer screening in time of immunotherapy
Cost-effectiveness and budget impact of lung cancer screening in time of immunotherapy Open
Lung cancer screening in high-risk population remains cost-effective when immunotherapy is offered to all stages. By shifting diagnoses from advanced to early stages, screening yielding substantial savings. These findings support LDCT scre…
View article: Stage‐ and histology‐specific sensitivity for the detection of lung cancer of the <scp>NELSON</scp> screening protocol—A modeling study
Stage‐ and histology‐specific sensitivity for the detection of lung cancer of the <span>NELSON</span> screening protocol—A modeling study Open
The Dutch–Belgian lung cancer (LC) screening trial (Nederlands–Leuvens Longkanker Screenings Onderzoek [NELSON]) demonstrated low‐dose computed tomography (CT) reduces LC mortality by 24% among men. The NELSON protocol differed from previo…
View article: Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors
Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors Open
Pembrolizumab is a cost-effective first-line treatment for patients with metNSCLC and PD-L1 ≥ 50% in the Netherlands when at least 10% of patients are long-term survivors. Without long-term survivors, this treatment is not cost-effective. …
View article: Incorporating High-Risk Individuals Beyond Smoking History Into Lung Cancer Screening in Hong Kong: A Cost-Effectiveness Study
Incorporating High-Risk Individuals Beyond Smoking History Into Lung Cancer Screening in Hong Kong: A Cost-Effectiveness Study Open
LCS with LDCT can be considered cost-effective in HK for high-risk individuals on the basis of smoking history and factors other than smoking history, contributing to the health benefits of the population. Our findings support a population…
View article: Applying and validating a quality management system for in-house developed medical software
Applying and validating a quality management system for in-house developed medical software Open
Introduction The legislation regarding in-house development of medical devices has changed substantially with the introduction of the Medical Device Regulation (MDR) in 2021. Practical guidelines regarding the implementation of a quality m…
View article: Presence of On-Target Resistant Mutation in Pre-Treatment Samples of ALK Fusion Gene Positive Lung Cancer Patients
Presence of On-Target Resistant Mutation in Pre-Treatment Samples of ALK Fusion Gene Positive Lung Cancer Patients Open
A subset of ALK+ non-small cell lung cancer (NSCLC) patients relapse on ALK inhibitor (ALKi) treatment due to on-target resistance mutations affecting the tyrosine kinase domain. Objective: In this study, we investigated the presence of mi…
View article: Lung cancer screening with volume computed tomography is cost-effective in Greece
Lung cancer screening with volume computed tomography is cost-effective in Greece Open
Objective This study aimed to assess the cost-effectiveness of lung cancer screening (LCS) employing volume-based low-dose computed tomography (LDCT) in contrast to the absence of screening, targeting an asymptomatic high-risk population i…
View article: Lung Nodule Management in Low-Dose CT Screening for Lung Cancer: Lessons from the NELSON Trial
Lung Nodule Management in Low-Dose CT Screening for Lung Cancer: Lessons from the NELSON Trial Open
Low-dose CT screening for lung cancer depicts millions of mostly benign nodules; this requires a risk-stratification protocol using nodule volume, growth, density, and other features to assess nodule malignancy risk.
View article: Distribution of Solid Lung Nodules Presence and Size by Age and Sex in a Northern European Nonsmoking Population
Distribution of Solid Lung Nodules Presence and Size by Age and Sex in a Northern European Nonsmoking Population Open
This study provides the prevalence and size distribution of solid lung nodules by age and sex in a Northern European nonsmoking population.
View article: Baseline Blood CD8+ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer
Baseline Blood CD8+ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer Open
Background: Tumor-infiltrating immune cells have been correlated with prognosis for patients treated with immune checkpoint inhibitor (ICI) treatment of various cancers. However, no robust biomarker has been described to predict treatment …
View article: Figure S3 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S3 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy Open
Figure S3: Identifying FRM0469-dextramer-positive CD8+ T cells.
View article: Figure S6 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S6 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy Open
Figure S6: Comparison of long and short read RNA gene expression quantification and transcript coverage bias.
View article: Figure S1 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S1 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy Open
Figure S1: RNA-guided tumor genome reconstruction.
View article: Figure S13 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S13 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy Open
Figure S13: In silico determined immunogenic properties of NOPs.
View article: Figure S11 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S11 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy Open
Figure S11: Example of a hidden NOP resulting from a complex chromosomal rearrangement in tumor sample LUN022.
View article: Figure S7 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S7 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy Open
Figure S7: Protein mass spectrometry results for A375 NOPs.
View article: Figure S16 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S16 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy Open
Figure S16: Expansion of FRM-specific CD8T cells after priming with relevant peptide in PBMC from healthy individuals.
View article: Figure S12 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S12 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy Open
Figure S12: Example of a genomic rearrangement resulting in the expression of multiple hidden NOPs in tumor sample BRE007.
View article: Figure S2 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S2 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy Open
Figure S2: Long RNA splice correction, isoform identification, and translation prediction.
View article: Figure S14 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S14 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy Open
Figure S14: A375 immunopeptidomics.
View article: Figure S11 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S11 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy Open
Figure S11: Example of a hidden NOP resulting from a complex chromosomal rearrangement in tumor sample LUN022.
View article: Data from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Data from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy Open
Identification of immunogenic cancer neoantigens as targets for therapy is challenging. Here, we integrate the whole-genome and long-read transcript sequencing of cancers to identify the collection of neo-open reading frame peptides (NOP) …